Ocugen Presents New Preclinical OCU200 Data at Vision and Ophthalmology Meet

 

• OCU200, a transferrin-tumstatin fusion protein, demonstrates potential to treat DME, DR, and Wet-AMD
  
  
• OCU200 reduced neovascularization and damage to retina and demonstrated comparable/slightly improved activity to aflibercept in an animal disease model
  

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the presentation of a pre-clinical study to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases. The data will be featured in a virtual poster presentation entitled “OCU200 (transferrin-tumstatin fusion protein): A potential therapeutic for DME, DR, and wet-AMD” at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, taking place May 1-7, 2021.

https://www.globenewswire.com/news-release/2021/05/06/2224408/0/en/Ocugen-Presents-New-Preclinical-OCU200-Data-at-the-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-2021-Annual-Meeting.html